Acarix AB (publ) (STO:ACARIX)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 328.44M |
| Revenue (ttm) | 7.36M |
| Net Income (ttm) | -48.09M |
| Shares Out | 1.16B |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 815,721 |
| Average Volume | 990,657 |
| Open | 0.291 |
| Previous Close | 0.293 |
| Day's Range | 0.277 - 0.293 |
| 52-Week Range | 0.191 - 0.471 |
| Beta | -0.15 |
| RSI | 47.28 |
| Earnings Date | Apr 15, 2026 |
About Acarix AB
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden. [Read more]
Financial Performance
In 2025, Acarix AB's revenue was 7.36 million, an increase of 18.69% compared to the previous year's 6.20 million. Losses were -48.09 million, -27.34% less than in 2024.
Financial StatementsNews
Acarix AB Earnings Call Transcript: Q4 2025
Q4 2025 saw 26% revenue growth, led by 87% U.S. market expansion and 64% increase in CADScor deliveries. Operating costs fell 23%, net loss improved 27%, and patch sales rose 73%. New payer and MDR certification support further global growth.
Acarix AB Earnings Call Transcript: Q3 2025
Q3 saw 137% global revenue growth, 95% increase in system deployments, and 49% reduction in net loss, driven by MENA expansion and robust U.S. performance. Gross margin remained strong at 85%, with expanding reimbursement and new clinical milestones.
Acarix AB Earnings Call Transcript: Q2 2025
Q2 saw strong U.S. growth with a 27% increase in system deliveries and 53% patch sales growth in H1, while gross margin rose to 94% and operating costs fell 24%. Revenue declined due to European divestment, but new global distribution and reimbursement wins position the company for future profitability.
Acarix AB Earnings Call Transcript: Q1 2025
Q1 2025 saw robust U.S. growth with system deliveries up 46% and patch sales up 104%, while global revenue rose 11%. Gross margin dipped due to a strategic sale, but patch margins remained strong. Key partnerships and clinical trials are advancing, with reimbursement progress ongoing.
Acarix AB Earnings Call Transcript: Q4 2024
Q4 2024 delivered 333% growth in systems installed, 88% patch revenue growth, and a 27% OpEx reduction, driven by a new subscription model and expanded U.S. market access. Achievements include a new CMS reimbursement code, key hires, and a SEK 87M capital raise, supporting a path to profitability by Q2 2026.
Acarix AB Earnings Call Transcript: Q3 2024
Q3 saw strong U.S. growth with 116% more patches sold and 89% higher patch sales, driven by new verticals and a key CMS reimbursement win. Gross margin rose to 90%, OpEx fell 12%, and a new clinical trial is set to support further expansion.
Acarix AB (publ) publishes Interim Report, April - June 2024
NEW YORK , Aug. 22, 2024 /PRNewswire/ -- Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its financial results for the second quarter of 2024. The company achieved...
Acarix AB Earnings Call Transcript: Q2 2024
Q2 saw record revenue and gross profit growth, driven by a new commercial model and strong US patch sales. Awaiting key CMS reimbursement decisions and private payer agreements, with significant market expansion and improved financials positioning for future growth.
Acarix Shares Begin Trading on the US-based OTCQB Market
NEW YORK , July 15, 2024 /PRNewswire/ -- Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, is pleased to announce that the Acarix shares (OTCQB: ACIXF) begin trading today on the O...